Multiple sclerosis: Getting personal with induced pluripotent stem cells

A. Di Ruscio; F. Patti; R. S. Welner; D. G. Tenen; G. Amabile

doi:10.1038/cddis.2015.179

Multiple sclerosis: Getting personal with induced pluripotent stem cells

A. Di Ruscio, F. Patti, R. S. Welner, D. G. Tenen, G. Amabile

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

Lingua originale	Inglese
Numero di articolo	e1806
Rivista	Cell Death and Disease
Volume	6
Numero di pubblicazione	7
DOI	https://doi.org/10.1038/cddis.2015.179
Stato di pubblicazione	Pubblicato - 1 lug 2015
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1038/cddis.2015.179

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{9a6b675e66d84b9da8b1724096269914,

title = "Multiple sclerosis: Getting personal with induced pluripotent stem cells",

abstract = "Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.",

author = "\{Di Ruscio\}, A. and F. Patti and Welner, \{R. S.\} and Tenen, \{D. G.\} and G. Amabile",

year = "2015",

month = jul,

day = "1",

doi = "10.1038/cddis.2015.179",

language = "English",

volume = "6",

journal = "Cell Death and Disease",

issn = "2041-4889",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - Multiple sclerosis

T2 - Getting personal with induced pluripotent stem cells

AU - Di Ruscio, A.

AU - Patti, F.

AU - Welner, R. S.

AU - Tenen, D. G.

AU - Amabile, G.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

AB - Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

UR - https://www.scopus.com/pages/publications/84954322927

U2 - 10.1038/cddis.2015.179

DO - 10.1038/cddis.2015.179

M3 - Review article

SN - 2041-4889

VL - 6

JO - Cell Death and Disease

JF - Cell Death and Disease

IS - 7

M1 - e1806

ER -

Multiple sclerosis: Getting personal with induced pluripotent stem cells

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo